Company profile
Wave Life Sciences Ltd.
NASDAQ: WVE · Healthcare · Biotechnology
#454 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
63CFH 54DQ 86GM 38SS 69
v0.1 · 65/100 weight · provisional
↑ filing timeliness, 3-yr revenue growth · ↓ growth stability, revenue growth (YoY)
Methodology →Revenue TTM
$65.4M
Rev growth YoY (TTM)
-30.4%
Net income (FY)
-$204.4M
Employees
317
as of 2026-08-18
Market cap
$1.0B
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$42.7M$42.7M2025
Net income-$204.4M-$204.4M2025
Operating income-$215.4M-$215.4M2025
Total assets$638.5M$638.5M2025
Liabilities$112.3M$112.3M2025
Equity$518.4M$518.4M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Wave Life Sciences Ltd.’s revenue?
Wave Life Sciences Ltd. booked $42.7M in FY2025 revenue, contracting 61% year over year — slower than 85% of Healthcare companies we track, at a -478.3% net margin.
Peers · Healthcare
HOOKIPA Pharma Inc.——Xilio Therapeutics, Inc.38DMedAvail Holdings, Inc.——Rubicon Organics Inc.63CSS Innovations International, Inc.53DCoherus Oncology, Inc.61CNeighbors
Middlesex →Key facts
CEOPaul Bolno
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeNASDAQ: WVE
Employees317
IPO date2015-11-11
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.